We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

Researchers Identify Metabolite That Tells Cells Whether To Repair DNA

Double helix structure of DNA.
Credit: iStock.
Listen with
Speechify
0:00
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: 1 minute

Metabolites called nucleotides are the building blocks of DNA and can impact cancer’s sensitivity or resistance to chemotherapy and radiation in brain cancer.


Findings from researchers at the University of Michigan Health Rogel Cancer Center, published in Cancer Discovery, show how a specific nucleotide metabolite, called GTP, controls responses to radiation and chemotherapy in an unexpected way.


“We learned that if you increase a cell’s GTP levels, it makes it really resistant to radiation or chemotherapy. Lowering GTP levels, the cell becomes much more sensitive,” said Daniel Wahl, M.D., Ph.D., associate professor of radiation oncology at Michigan Medicine and senior author of this paper.

Want more breaking news?

Subscribe to Technology Networks’ daily newsletter, delivering breaking science news straight to your inbox every day.

Subscribe for FREE

Researchers have long known that levels of nucleotides like GTP control how fast DNA damage is repaired, which in turn controls sensitivity to therapies.


Researchers previously thought that this only happened because nucleotides are the building blocks that form DNA. But these findings uncover an entirely new way that nucleotides control DNA repair.


“GTP impacts resistance or sensitivity to treatment not just because it’s a building block of DNA, as we previously thought,” Wahl continued.


“Instead of only affecting the physical structure of the DNA, it also acts as a signaler. The levels of GTP turn on a signaling pathway and give cells instructions to repair damaged DNA.”


What’s more, Wahl and collaborator Weihua Zhou, Ph.D., found this to be true for normal tissue in addition to cancer cells.


“It’s a generalizable finding,” said Zhou, research assistant professor of radiation oncology and first author of the study.


“In the future, we’d like to develop therapeutics that leverage the relationship between GTP and DNA damage response, both to make cancer cells more sensitive to chemotherapy and radiation and also to boost GTP levels to protect normal tissue from damage.”


Wahl and a team of researchers have an ongoing clinical trial for patients with brain cancer focused on the role of GTP in treatment responses.


Wahl says these findings are fundamental biologic discovery that translates into clinical applications for this trial and potential future trials.


“We knew that depleting GTP might make brain cancers respond better to chemotherapy and radiation. Now these findings show why that's happening,” Wahl said.


The discovery that GTP acts as a signaler helps explain the biological underpinnings of why focusing on GTP is a worthwhile pursuit and could help researchers figure out which patients will derive the most benefit from GTP modulators in the clinical trial.


“When the signaling pathway is active, the cancer is resistant to radiation and chemotherapy,” Wahl continued. “These findings might help us select the right patients for the next line of clinical trials.


Reference: Zhou W, Zhao Z, Lin A, et al. GTP signaling links metabolism, DNA repair, and responses to genotoxic stress. Cancer Discovery. 2023. doi: 10.1158/2159-8290.CD-23-0437


This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.